SavedAdd your journal

Journals / Journal of Clinical and Experimental Investigations / 2026 / Cilt: 1 Sayı: 1

The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia

Osman Yokuş
Özlem Şahin Balcık
Murat Albayrak
Pages
68–70
Publication Date
2010-03-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he
📊
Key Findings & Data:The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he
💡
Conclusion & Impact:The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Kronik lenfositik lösemi · fludarabin-siklofosfamid tedavisi · hematolojik toksisite

Abstract

The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he

🔖

Cite This Article

Yokuş, O., Balcık, Ö. Ş., Albayrak, M. (2010). The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Investigations, Cilt: 1 Sayı: 1, 68–70. https://doi.org/10.5799/ahinjs.01.2010.01.0014

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
  2. Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
  3. Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
  4. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
  5. Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
  6. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
  7. Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.